Archives

All posts by Cited in article

Cannabidiol (CBD) may prevent haloperidol-induced orofacial dyskinesia, according  to new research being published by the journal Brain, Behavior, and Immunity; the research was epublished by the National Institute of Health.

“The chronic use of drugs that reduce the dopaminergic neurotransmission can cause a hyperkinetic movement disorder called tardive dyskinesia (TD)”, states the study’s abstract. “The pathophysiology of this disorder is not entirely understood but could involve oxidative and neuroinflammatory mechanisms. Cannabidiol (CBD), the major non-psychotomimetic compound present in Cannabis sativa plant, could be a possible therapeutic alternative for TD.”

The study states that “This phytocannabinoid shows antioxidant, anti-inflammatory and antipsychotic properties and decreases the acute motor effects of classical antipsychotics. The present study investigated if CBD would attenuate orofacial dyskinesia, oxidative stress and inflammatory changes induced by chronic administration of haloperidol in mice.”

Furthermore, researchers “verified in vivo and in vitro (in primary microglial culture) whether these effects would be mediated by PPARγ receptors. The results showed that the male Swiss mice treated daily for 21 days with haloperidol develop orofacial dyskinesia. Daily CBD administration before each haloperidol injection prevented this effect.”

Mice treated with haloperidol “showed an increase in microglial activation and inflammatory mediators in the striatum. These changes were also reduced by

Read More Here…

Judges in Seattle have agreed to clear past misdemeanor convictions for marijuana possession that were prosecuted before marijuana was legalized in Washington, reports the Seattle Times.

All seven judges of the Seattle Municipal Court have signed an order setting out a process for vacating the cases. The ruling follows City Attorney Pete Holmes’ filing of a motion in April asking the court to vacate the convictions.

In his motion, Holmes argued that possessing small amounts of marijuana is no longer illegal and clearing past convictions would right the injustices of a drug war that targeted people of color.

About 542 people could be affected. The ruling covers from about 1996 – when municipal courts, rather than county district courts, began handling those misdemeanors – to 2010 when Holmes became city attorney and stopped prosecuting low-level, non-violent marijuana cases.

“Insomuch as the conduct for which the defendant was convicted is no longer criminal, setting aside the conviction and dismissing the case serves the interests of justice,” wrote the judges in their ruling.

Read More Here…

A Maine restaurant that had been sedating lobsters with cannabis before boiling them alive is now under investigation for the culinary preparation, according to media reports. Charlotte Gill, the owner of Charlotte’s Legendary Lobster Pound in Southwest Harbor, Maine, had been offering the option to patrons ordering live Maine lobster at the restaurant.

But state regulators have taken notice and now the Maine Health Inspection Program is investigating the practice, a spokesperson for the Department of Health and Human Services has confirmed.

Gill is a registered medical marijuana caregiver and grows the cannabis she uses for the lobster. But a spokesman for the Maine Medical Marijuana program, David Heidrich, said in an email that the use of cannabis was not appropriate.

“Medical marijuana may only be grown for and provided to persons with a marijuana recommendation from a qualified medical provider,” he said. “Lobsters are not people.”

Temporarily Off the Menu

The restaurant has temporarily stopped selling the “high-end lobster,” as Gill calls it, but she hopes to be able to offer it again.

“After being contacted by the state, and upon reviewing its present laws and codes applicable to this arena, and then making a few minor adjustments to our procedure, we are

Read More Here…

Cannabinoids may provide a potential treatment option for prostate cancer, according to a new study published by the journal The Prostate.

“Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer”, states researchers. In the present study, they “explored the anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer.”

For the study, “Established prostate cancer cells (PC3, DU145, LNCaP) were treated with varying concentrations of WIN”, and “Cell proliferation was determined by the MTS assay.” The anti-migration and anti-invasive potential of WIN “was examined by the wound healing assay and the matrigel invasion assay.” Cell cycle analysis was performed by flow cytometry, and mechanistic studies were performed by Western blot.

Animals were randomized into two groups: saline control and WIN (5 mg/kg), delivered by intraperitoneal injection three times per week for 3 weeks.

“WIN significantly reduced prostate cancer cell proliferation, migration, invasion, induced apoptosis, and arrested cells in Go/G1 phase in a dose-dependent manner”, claim researchers.

They conclude; “The following study provides evidence supporting the use of WIN as a novel therapeutic for prostate cancer.”

For more info on this study, click here.

Read More Here…

Municipal court judges in Seattle, Washington, have agreed to vacate misdemeanor marijuana possession convictions that were prosecuted before the legalization of cannabis. The judges’ decision could affect up to 542 defendants in cases prosecuted between 1996 and 2010.

Earlier this month, the judges issued an order outlining a process to clear the records of those with misdemeanor possession convictions.

“Insomuch as the conduct for which the defendant was convicted is no longer criminal, setting aside the conviction and dismissing the case serves the interests of justice,” the judges wrote.

The judges directed the city attorney’s office to provide the court with the last known address of the 542 defendants, who will be notified of the intention to clear their records. The defendants will have the opportunity to object and ask the court for an individualized ruling instead.

City Attorney Pete Holmes said after the order that Seattle should “take a moment to recognize the significance” of the court’s decision, according to media reports.

“We’ve come a long way, and I hope this action inspires other jurisdictions to follow suit,” Holmes added.

Mayor Jenny Durkan said the move has the potential to improve the lives of those with past convictions.

“For

Read More Here…

Shoppers Drug Mart has received Health Canada’s approval to be a licensed medical marijuana producer, opening the door for the pharmacy giant to dispense medical cannabis to patients.

This comes after Shoppers in October 2016 applied to Health Canada to become a licensed medical marijuana producer.

“As trusted medication experts, we believe pharmacists have an important role to play in the safe and informed use of medical cannabis, and this is the first step in our journey to provide medical cannabis to our patients,” said Loblaw spokeswoman Catherine Thomas in an emailed statement. “We will share more information about our plans in the coming weeks.”

Under the current Health Canada regulations for medical pot, the only legal distribution method is by mail order from licensed producers direct to patients. A cannabis sales license from Health Canada is also required to dispense medical marijuana to patients.

– Read the entire article at The Star.

Read More Here…

Toronto-based company AHLOT is offering up to $1,000 a month to 5 pot aficionados.

Getting paid to smoke pot is no longer a toker’s daydream.

A cannabis firm is looking to hire five pot aficionados from across the country to sample the company’s wares and get paid to do it.

Toronto-based company AHLOT is offering up to $1,000 a month to five “cannabis connoisseurs” to sample various strains of marijuana.

– Read the entire article at CBC News.

Read More Here…

Daily cannabis use is associated with greater odds of retention in treatment among those addicted to opioids, according to a new study published in the journal Addiction, and epublished online by the National Institute of Health.

“Cannabis use is common among people on opioid agonist treatment (OAT), causing concern for some care providers”, states the study. “However, there is limited and conflicting evidence on the impact of cannabis use on OAT outcomes. Given the “critical role of retention in OAT in reducing opioid-related morbidity and mortality”, researchers “aimed to estimate the association of at least daily cannabis use on the likelihood of retention in treatment among people initiating OAT.” As a secondary aim researchers “tested the impacts of less frequent cannabis use.”

The study comprised a total of 820 people who use illicit drugs (PWUD), who initiated OAT between December 1996 and May 2016. . Participants were followed for a median of 81 month.

The primary outcome was retention in OAT, defined as remaining in OAT (methadone or buprenorphine/naloxone-based) for two consecutive 6-month follow-up periods, and the primary explanatory variable was cannabis use (at least daily versus less than daily) during the same 6-month period. “Confounders assessed included: socio-demographic characteristics, substance use patterns and social-structural exposures.”

In adjusted analysis, “at least daily cannabis use

Read More Here…